FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1989286609> ?p ?o ?g. }

• W1989286609 endingPage "135" @default.
• W1989286609 startingPage "135" @default.
• W1989286609 abstract "Concurrent chemoradiotherapy (CCR) followed or preceded by full-dose chemotherapy seems to be a standard treatment for unresectable non-small cell lung cancer (NSCLC). Gemcitabine is a strong radiosensitizer, and a phase I study confirmed the feasibility of CCR with low-dose gemcitabine administered twice-weekly in NSCLC patients. Consequently, we designed a prospective, multicentric, phase II trial to evaluate the efficacy and toxicity of this approach, following induction chemotherapy with cisplatin and gemcitabine. We included patients with unresectable stage III NSCLC, no pleural effusion, adequate pulmonary, renal, liver and hematological functions, Karnofsky index >70 and planned treated volume (PTV) <2200 cm3. Treatment consisted of 3 cycles of cisplatin (100 mg/m2, d1) and gemcitabine (1250 mg/m2, d1 and 8) q3w, followed by CCR (gemcitabine 50 mg/m2 on Mondays and Thursdays and radiotherapy 68.4 Gy, 1.8 Gy qd). After the inclusion of 22 patients (group A), an unacceptable toxicity was detected. Thus, cisplatin dose was reduced to 70 mg/m2, and gemcitabine dose was adjusted to 35 mg/m2 during CCR. Another 34 patients (33 eligible, group B) were included. Five patients in group A and 6 patients in group B discontinued the study treatment during induction. Thus, 17 and 27 patients, respectively initiated CCR. Hematological toxicity (grades III and IV) was particularly relevant in group A during this phase, with 35 and 23% of thrombopenia and neutropenia, respectively. Nonhematological grades III–IV toxicity of chemoradiation was significant and similar in groups A and B: esophagitis 35.2 and 33.3% and pneumonitis 23.5 and 25.9%, respectively. 40.9% of patients in group A vs. 57.5% in group B completed treatment. Overall response (intention-to-treat analysis) was 68.1% in group A and 63.5% in group B. Median survival was 17.7 months for the whole group with a mean follow-up of 41.2 months. 20% of patients were alive at 3 years. Long-term results of this schedule are encouraging. However, nonhematological toxicity of chemoradiation is substantial and different strategies should be tested to minimize it." @default.
• W1989286609 created "2016-06-24" @default.
• W1989286609 creator A5006338325 @default.
• W1989286609 creator A5018998603 @default.
• W1989286609 creator A5020875800 @default.
• W1989286609 creator A5023793074 @default.
• W1989286609 creator A5028088359 @default.
• W1989286609 creator A5028414274 @default.
• W1989286609 creator A5036086195 @default.
• W1989286609 creator A5059806908 @default.
• W1989286609 creator A5062301570 @default.
• W1989286609 date "2009-09-01" @default.
• W1989286609 modified "2023-10-18" @default.
• W1989286609 title "1248 A phase 1 study of S-1 with 3-week schedule in patients with biliary tract cancer of normal and varying degrees of liver dysfunction" @default.
• W1989286609 doi "https://doi.org/10.1016/s1359-6349(09)70460-4" @default.
• W1989286609 hasPublicationYear "2009" @default.
• W1989286609 type Work @default.
• W1989286609 sameAs 1989286609 @default.
• W1989286609 citedByCount "0" @default.
• W1989286609 crossrefType "journal-article" @default.
• W1989286609 hasAuthorship W1989286609A5006338325 @default.
• W1989286609 hasAuthorship W1989286609A5018998603 @default.
• W1989286609 hasAuthorship W1989286609A5020875800 @default.
• W1989286609 hasAuthorship W1989286609A5023793074 @default.
• W1989286609 hasAuthorship W1989286609A5028088359 @default.
• W1989286609 hasAuthorship W1989286609A5028414274 @default.
• W1989286609 hasAuthorship W1989286609A5036086195 @default.
• W1989286609 hasAuthorship W1989286609A5059806908 @default.
• W1989286609 hasAuthorship W1989286609A5062301570 @default.
• W1989286609 hasConcept C126322002 @default.
• W1989286609 hasConcept C143998085 @default.
• W1989286609 hasConcept C2776256026 @default.
• W1989286609 hasConcept C2776694085 @default.
• W1989286609 hasConcept C2777063308 @default.
• W1989286609 hasConcept C2778239845 @default.
• W1989286609 hasConcept C2778424827 @default.
• W1989286609 hasConcept C2780258809 @default.
• W1989286609 hasConcept C29730261 @default.
• W1989286609 hasConcept C31760486 @default.
• W1989286609 hasConcept C71924100 @default.
• W1989286609 hasConcept C90924648 @default.
• W1989286609 hasConceptScore W1989286609C126322002 @default.
• W1989286609 hasConceptScore W1989286609C143998085 @default.
• W1989286609 hasConceptScore W1989286609C2776256026 @default.
• W1989286609 hasConceptScore W1989286609C2776694085 @default.
• W1989286609 hasConceptScore W1989286609C2777063308 @default.
• W1989286609 hasConceptScore W1989286609C2778239845 @default.
• W1989286609 hasConceptScore W1989286609C2778424827 @default.
• W1989286609 hasConceptScore W1989286609C2780258809 @default.
• W1989286609 hasConceptScore W1989286609C29730261 @default.
• W1989286609 hasConceptScore W1989286609C31760486 @default.
• W1989286609 hasConceptScore W1989286609C71924100 @default.
• W1989286609 hasConceptScore W1989286609C90924648 @default.
• W1989286609 hasIssue "2" @default.
• W1989286609 hasLocation W19892866091 @default.
• W1989286609 hasOpenAccess W1989286609 @default.
• W1989286609 hasPrimaryLocation W19892866091 @default.
• W1989286609 hasRelatedWork W1972888300 @default.
• W1989286609 hasRelatedWork W2026791198 @default.
• W1989286609 hasRelatedWork W2050954759 @default.
• W1989286609 hasRelatedWork W2056002207 @default.
• W1989286609 hasRelatedWork W2085978374 @default.
• W1989286609 hasRelatedWork W2100029565 @default.
• W1989286609 hasRelatedWork W2350964097 @default.
• W1989286609 hasRelatedWork W2379223378 @default.
• W1989286609 hasRelatedWork W2381460883 @default.
• W1989286609 hasRelatedWork W3032349186 @default.
• W1989286609 hasVolume "7" @default.
• W1989286609 isParatext "false" @default.
• W1989286609 isRetracted "false" @default.
• W1989286609 magId "1989286609" @default.
• W1989286609 workType "article" @default.